Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of samarium-153 lexidronam plus docetaxel/prednisone versus docetaxel/prednisone in taxane-naive metastatic hormone-refractory prostate cancer
2008-004628-21Phase 3Active
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Oct 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Samarium-153 lexidronam + docetaxel + prednisone with Docetaxel + prednisone (2 arms). Primary endpoint: Time to progression. Started Oct 2008; status: active.
02
Drugs
samarium-153 lexidronamdocetaxelprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-004628-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004628-21.